SIETES :: 93213 citas

Resultados de la búsqueda por DEPRESIÓN REFINAR BÚSQUEDA

1.

Nguyen D-D, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh Q-D. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol 2020:11 de noviembre. [Ref.ID 103784]

2.

Davis AK, Barrett FS, May DG, et al.. Effects of psilocybin-assisted therapy on major depressive disorderA randomized clinical trial. JAMA Psychiatry 2020:4 de noviembre. [Ref.ID 103765]

3.

Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS One 2020;5:30 de septiembre. [Ref.ID 103735]

4.

Anónimo. In brief: Neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020;62:65. [Ref.ID 103638]

5.

Anónimo. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. U.S. Food and Drug Administration 2020:4 de marzo. [Ref.ID 103559]

6.

Marsh S. Suicides linked to acne drug Roaccutane as regulator reopens inquiry. The Guardian 2019:27 de diciembre. [Ref.ID 103237]

7.

Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, Wimberley T, Thygesen M, Bang Madsen K, Timmerman A, Schendel D, McGrath JJ, Mortensen PB, Pedersen CB. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry 2019:20 de noviembre. [Ref.ID 103222]

8.

Iacobucci G. NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms. BMJ 2019;367:18 de octubre. [Ref.ID 103202]

9.

Mamdani M, Gomes T, Greaves S, Manji S, Juurlink DN, Tadrous M, Kennedy SH, Antoniou T. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. JAMA Network Open 2019;2:e1913304. [Ref.ID 103200]

10.

Moncrieff J. Re: Esketamine for treatment resistant depression. Putting drug company interests over the public good. BMJ 2019;366:23 de septiembre. [Ref.ID 103196]

11.

Gobbi G, Atkin T, Zytnski T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. JAMA Psychiatry 2019;76:13 de febrero. [Ref.ID 103030]

12.

Valles-Colomer M, Falongy G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, Schiweck C, Kurilshikov A, Joossens M, Wijmenga C, Claes S, Van Oudenhove L, Zhernakova A, Vieira-Silva S, Raes J. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019:4 de febrero. [Ref.ID 103027]

13.

Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]

14.

Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews 2018:24 de noviembre. [Ref.ID 102889]

15.

King MA. Pregabalin and gabapentin associated with depression and suicidal ideation. BMJ 2018;363:29 de noviembre. [Ref.ID 102862]

16.

Kim J-M, Stewart R, Lee Y-S, Lee H-J, Kim MC, Kim J-W, Kang H-J, Bae K-Y, Kim S-W, Shin I-S, Hong YJ, Kim JH, Ahn Y, Jeong MH, Soon J-S. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome. A randomized clinical trial. JAMA 2018;320:350-8. [Ref.ID 102816]

17.

Begley S. ‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims — and finding some truth. STAT 2018:23 de agosto. [Ref.ID 102810]

18.

Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]

19.

Okun MS. Demoralization in Parkinson disease. Journal Watch 2018:30 de abril. [Ref.ID 102578]

20.

Hopcroft K. Effectiveness of antidepressants - should we rethink treatment duration?. BMJ 2018;361:24 de abril. [Ref.ID 102576]